A prospective, randomized, single center, phase II study of Fluzoparib combined with ADT for high risk localized prostate cancer with homologous recombination repair abnormalities before prostatectomy
Latest Information Update: 02 Dec 2020
At a glance
- Drugs Fuzuloparib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 02 Dec 2020 New trial record